These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6334429)

  • 1. Effects of carbidopa on the cerebral accumulation of exogenous L-5-hydroxytryptophan in mice.
    Magnussen I
    Acta Pharmacol Toxicol (Copenh); 1984 Sep; 55(3):199-202. PubMed ID: 6334429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
    Magnussen I; Jensen TS; Rand JH; Van Woert MH
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain.
    Löscher W; Pagliusi SR; Müller F
    Neuropharmacology; 1984 Sep; 23(9):1041-8. PubMed ID: 6083501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of carbidopa on the concentration of rat pineal and hypothalamic indoleamines.
    Oxenkrug GF; McIntyre IM; Novak EA; Hryhorczuk LM; Frohman CE
    J Pineal Res; 1984; 1(4):349-53. PubMed ID: 6085877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
    Smarius LJ; Jacobs GE; Hoeberechts-Lefrandt DH; de Kam ML; van der Post JP; de Rijk R; van Pelt J; Schoemaker RC; Zitman FG; van Gerven JM; Gijsman HJ
    J Psychopharmacol; 2008 Jun; 22(4):426-33. PubMed ID: 18308795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin formation in nonblood-perfused rat kidneys.
    Stier CT; McKendall G; Itskovitz HD
    J Pharmacol Exp Ther; 1984 Jan; 228(1):53-6. PubMed ID: 6607338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of serotonin by rat kidneys in vivo.
    Stier CT; Itskovitz HD
    Proc Soc Exp Biol Med; 1985 Dec; 180(3):550-7. PubMed ID: 3878522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The origin of blood 5-hydroxyindoleacetic acid following L-hydrazine-alpha-methyldopa (MK-486).
    Warsh JJ; Stancer HC
    Eur J Pharmacol; 1975 May; 32(1):128-32. PubMed ID: 1080116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to the increased locomotor activity produced by L-5-hydroxytryptophan following peripheral decarboxylase inhibition in mice.
    Magyar RL; Gillin JC; Wyatt RJ
    Psychopharmacology (Berl); 1978 Apr; 56(3):343-50. PubMed ID: 418444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The origin of blood k-hydroxyindoleacetic acid following L-hydrazino-alpha-methyldopa (MK-486).
    Warsh JJ; Stancer HC
    Eur J Pharmacol; 1975 May; 32(1):128-32. PubMed ID: 1080115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA; Johnson JC
    Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency.
    Lado-Abeal J; Graña M; Rey C; Cabezas-Cerrato J
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):203-7. PubMed ID: 9828908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of administration of 5-hydroxytryptophan and an inhibitor of L-aromatic amino acid decarboxylase on glucose metabolism in rat brain.
    Wong KL; Tyce GM
    Neurochem Res; 1979 Apr; 4(2):277-87. PubMed ID: 313531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral conversion of L-5-hydroxytryptophan to serotonin induces drinking in rats.
    Kikta DC; Threatte RM; Barney CC; Fregly MJ; Greenleaf JE
    Pharmacol Biochem Behav; 1981 Jun; 14(6):889-93. PubMed ID: 6973156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of tolerance to the wet-dog shake behaviour but not the increase in seizure threshold induced by L-5-hydroxytryptophan during continued treatment in rats.
    Pagliusi SR; Löscher W
    Psychopharmacology (Berl); 1985; 86(1-2):118-24. PubMed ID: 2410943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.
    Magnussen I; Engbaek F
    Acta Pharmacol Toxicol (Copenh); 1978 Jul; 43(1):36-42. PubMed ID: 309271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that the accumulation of 5-hydroxytryptamine in the liver but not in the brain may cause the hypoglycaemia induced by 5-hydroxytryptophan.
    Endo Y
    Br J Pharmacol; 1985 Jul; 85(3):591-8. PubMed ID: 3875380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [(11)C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.
    Visser AK; Ramakrishnan NK; Willemsen AT; Di Gialleonardo V; de Vries EF; Kema IP; Dierckx RA; van Waarde A
    J Cereb Blood Flow Metab; 2014 Jan; 34(1):118-25. PubMed ID: 24084697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral bioavailability of an L-5-HTP/carbidopa tablet].
    Obach R; Pruñonosa J; Vallés J; Vallés JM
    Arch Farmacol Toxicol; 1982 Dec; 8(3):179-82. PubMed ID: 6985117
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of peripheral mechanisms in the behavioral effects of 5-hydroxytryptophan.
    Carter RB; Dykstra LA; Leander JD; Appel JB
    Pharmacol Biochem Behav; 1978 Aug; 9(2):249-53. PubMed ID: 309609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.